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Abstract When cells are stimulated by mitogens, extracellular
signal-regulated kinase (ERK) is activated by phosphorylation of
its regulatory threonine (Thr) and tyrosine (Tyr) residues. The
inactivation of ERK may occur by phosphatase-mediated
removal of the phosphates from these Tyr, Thr or both residues
together. In this study, antibodies that selectively recognize all
combinations of phosphorylation of the regulatory Thr and Tyr
residues of ERK were developed, and used to study the
inactivation of ERK upon mitogenic stimulation. We found that
inactivation of ERK in the early stages of mitogenic stimulation
involves separate Thr and Tyr phosphatases which operate
differently in the nucleus and in the cytoplasm. Thus, ERK is
differentially regulated in various subcellular compartments to
secure proper length and strength of activation, which eventually
determine the physiological outcome of many external signals.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The response of cells to extracellular stimuli is mediated by
an array of intracellular signaling pathways that relay the
extracellular information to di¡erent subcellular compart-
ments. An important component in many intracellular signal-
ing events is the extracellular signal-regulated kinase (ERK)
which belongs to the family of mitogen-activated protein ki-
nases (MAPKs) [1^4]. The three known isoforms of ERK
(ERK1, ERK1b and ERK2 [5]) are protein serine/threonine
(Ser/Thr) kinases, which are phosphorylated and activated by
the upstream kinases, MEK1 and MEK2 [1]. These latter ki-
nases phosphorylate ERKs on regulatory Thr and tyrosine
(Tyr) residues which are localized in the activation loop of
ERK [6]. Structurally, the phosphorylation of these two reg-
ulatory residues causes a depression in the surface of the sub-
strate binding site of ERK, which consequently positions sub-
strates towards the Q-phosphate of ATP, and allows
phosphorylation to occur [7]. These changes induce a full
catalytic activity (V5 Wmol/min/mg) of ERK, which is 5^6
orders of magnitude higher than its basal activity. Interest-
ingly, ERKs are activated either when both Thr and Tyr
residues are phosphorylated; phosphate incorporation into
either one of them does not change their catalytic activity
[8].
MEK appears to be the only kinase capable of phosphor-
ylating the two activating residues of ERK [9]. Kinetic anal-
ysis indicated that phosphorylation of the Tyr residue of ERK
precedes that of the Thr residue [10,11]. Detailed in vitro
studies [11,12] revealed that phosphorylation of these two res-
idues is non-processive, i.e. that MEK must dissociate from
ERK after the ¢rst phosphorylation and rebind for the second
phosphorylation to proceed. However, the two phosphory-
lation events are cooperative and occur almost simultaneously
[13]. Thus, the amount of inactive mono-Tyr phosphorylated
ERK after stimulation should be minimal, even though mono-
phosphorylated species of ERK may exist due to inactivation
processes. Inactivation of ERK usually occurs by dephosphor-
ylation, and may occur by removal of phosphate from Tyr
alone, Thr alone, or from both residues together [8]. In fact,
protein Tyr phosphatase (PTP), Ser/Thr protein phosphatase
(PP) and dual speci¢city phosphatase (MKPs) have been im-
plicated in the inactivation of ERK [14^16]. Since MKPs
are usually induced proteins [17], the short term dephosphor-
ylation of ERK probably produces mono-phosphorylated
ERKs.
Previously [18], we prepared a monoclonal antibody (mAb)
(MAPK-YT; also referred to as mAb-YT) that speci¢cally
recognizes the phosphorylated Thr and Tyr residues of the
activation loop of ERK. This antibody was successfully
used to study ERK activation in various systems [18^21].
Herein, a set of mAbs against the various phosphorylation
states of ERK were prepared, and together with the mAb-
TY, they were used to study the inactivation of ERK. We
found that the nuclear inactivation of ERK involves an initial
dephosphorylation by a Ser/Thr phosphatase, whereas the in-
activation of ERK in the cytoplasm is initiated by a Tyr
phosphatase(s). Thus, the activation of ERK after mitogenic
stimulation is regulated in both a temporal and spatial man-
ner by di¡erent phosphatases.
2. Materials and methods
2.1. Bu¡ers and cells
Bu¡er A: 50 mM L-glycerophosphate, 1.5 mM EGTA, 1 mM
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EDTA, 1 mM DTT, 1 mM sodium orthovanadate. Bu¡er H: bu¡er A
containing 1 mM benzamidine, 10 Wg/ml aprotinin, 10 Wg/ml leupep-
tin, 1 mM PMSF, 2 Wg/ml pepstatin. Chinese hamster ovary cells
stably transfected by ErbB1 (CHO.E) were a generous gift from Dr.
Y. Yarden (The Weizmann Institute of Science, Rehovot, Israel).
CHO.E cells were grown in 50% DMEM/50% F12 supplemented
with 10% fetal calf serum (FCS).
2.2. Antibody development
mAbs were raised against peptides containing the 11 amino acid
HTGFLTEYVAT corresponding to the ERK activation loop either
Thr-phosphorylated (PT-TEY), Tyr-phosphorylated (PY-TEY) or
non-phosphorylated (NP-TEY). For immunization, the peptides
were conjugated to KLH using glutaraldehyde. BALB/c mice were
immunized and their spleen cells were fused with NS-1 mouse myelo-
ma cells. Hybridoma supernatants were screened for speci¢c anti-
bodies by enzyme-linked immunosorbent assay (ELISA) on a bovine
serum albumin (BSA) conjugate of the above peptides (peptide-
BSA), and by Western blotting of cell extracts. The following
clones were selected: ERK-YNP (termed mAb-155) was originated
against the NP-TEY peptide; ERK-PT115 (mAb-115) was originated
against the PT-TEY peptide; and ERK-PY193 (mAb-193) was
originated against the PY-TEY peptide. In this study, we used
the ascitic £uid of these and of the MAPK-YT (mAb-TY) clones
(V4 mg/ml). All the above antibodies are commercially available
from Sigma.
2.3. ELISA and dot blot
Antibody speci¢city was determined by ELISA and dot blot. Wells
in a 96 well plate were coated overnight with 2 Wg/ml of peptide-BSA
conjugates and washed. After incubation with dilutions of each anti-
body (1 h), the wells were washed, incubated with peroxidase-conju-
gated secondary antibodies (1 h) and developed according to the
manufacturer’s instructions. For competitive ELISA, the antibody
binding to the peptide-BSA conjugate was competed with 1 ng/ml^
100 Wg/ml (1 h) of non-conjugated NP-TEY, PT-TEY, PY-TEY, or
doubly phosphorylated (DP-TEY) peptides, as well as with doubly
phosphorylated peptides of JNK (pTPpY) or p38 MAPK (pTGpY).
For dot blot, di¡erent peptide-BSA conjugates were spotted on
a nitrocellulose membrane. The membrane was blocked by BSA
and blotted with antibodies followed by secondary antibodies conju-
gated with alkaline phosphatase. The staining was developed by NBT/
BCIP.
2.4. Western blot analysis
CHO.E cells were grown in 10 cm plates and serum-starved (0.1%
FCS) for 16 h. After stimulation, the cells were washed twice with ice-
cold phosphate-bu¡ered saline (PBS) and once with ice-cold bu¡er A.
Cells were harvested as previously described [22] with 0.3 ml of bu¡er
H followed by sonication (2U7 s, 40 W) and centrifugation
(15 000Ug, 15 min, 4‡C). The supernatants, which contained cytosolic
proteins, were collected and aliquots from each sample (20 Wg) were
separated on 10% sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) followed by Western blotting. The di¡erent
phosphorylation states of ERK were detected by probing the blots
with mAb-TY, mAb-115, mAb-155, mAb-193 or KGPY (Zymed). To
separate Thr phosphorylated ERK from non-phosphorylated ERK,
0.4% bisacrylamide was used instead of 0.8% when casting the SDS^
polyacrylamide gel. Total ERK was detected with 7884 polyclonal
antibody (pAb 1:20 000; [23]). The blots were developed with alkaline
phosphatase or horseradish peroxidase-conjugated anti-mouse or anti-
rabbit Fab antibodies (Jackson).
2.5. Immuno£uorescent staining
Serum-starved (0.1% FCS, 40 h) CHO.E cells were treated with
epidermal growth factor (EGF) (50 ng/ml) for up to 15 min. Sub-
sequently, the cells were washed with PBS and ¢xed in 3% formalde-
hyde in PBS for 20 min. Following additional washes with PBS, the
cells were permeabilized with methanol at 310‡C for 10 min. Staining
was performed as previously described [24] by 45 min incubation with
pAb 7884, or the mAbs-TY, 115, 155 or 193, followed by 45 min
incubation with appropriate secondary antibodies conjugated to Cy3
or FITC. Fluorescence was viewed with a £uorescent microscope
(Zeiss).
3. Results and discussion
3.1. Preparation and characterization of anti-phospho-ERK
antibodies
In order to study the mechanism of ERK phosphorylation
and dephosphorylation in vivo, a set of mAbs which could
distinguish between the di¡erent phosphorylation states of
ERKs was developed. The antigens used to generate these
mAbs were 11 amino acid peptides derived from the activa-
tion loop of ERK2 (residues 178^188) with no incorporated
phosphate (NP-TEY), mono-phosphorylated on Thr (PT-
TEY) or mono-phosphorylated on Tyr (PY-TEY). Three
mAbs were obtained: ERK-YNP (referred to as mAb-155),
ERK-PT115 (referred to as mAb-115) and ERK-PY193 (re-
ferred to as mAb-193), which were raised against NP-TEY,
PT-TEY and PY-TEY, respectively.
In a direct ELISA (Fig. 1A), in which BSA-conjugated
peptides were used as a recognition matrix, mAb-155 recog-
nized the Thr-phosphorylated peptide (PT-TEY-BSA) 10-fold
Fig. 1. Speci¢city of the anti-phospho-ERK antibodies using ELISA
and dot blot assay. A: 96 Well plates were coated with the appro-
priate BSA-conjugated peptides: PT- b, PY- a, DP- F or NP- E
TEY (1 Wg/ml), followed by incubation with the various antibodies.
The binding was detected with peroxidase-conjugated goat anti-
mouse antibody. B: The same BSA-conjugated peptides as in A
were spotted on a nitrocellulose membrane. The membrane was
blocked by 2% BSA and incubated with di¡erent antibodies (TY,
155, 115, 193 or GPY) followed by alkaline phosphatase-conjugated
second antibodies. These results were reproduced three times.
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better (50% binding: 0.016 Wg/ml) than non-phosphorylated
peptide conjugated to BSA (NP-TEY-BSA, 50% binding:
0.085 Wg/ml). mAb-115, mainly recognized the PT-TEY-BSA
(50% binding: 0.04 Wg/ml) and mAb-193 speci¢cally recog-
nized the Tyr-phosphorylated form of the peptide (PY-TEY-
BSA, 50% binding: 0.015 Wg/ml). A pAb that recognizes
phosphorylated Tyr residues in general (KGPY) recognized
both PY-TEY-BSA (50% binding: 0.5 Wg/ml) and DP-TEY-
BSA (50% binding: 0.7 Wg/ml), both of which have phos-
phates incorporated to their Tyr residue.
Similar results to those obtained with the ELISA were also
obtained in a dot blot assay (Fig. 1B). As previously reported
[18], mAb-TY recognized only DP-ERK-BSA. MAb-155 rec-
ognized mainly PT-ERK-BSA, but also NP-ERK-BSA, mAb-
115 recognized both PT-ERK-BSA and DP-ERK-BSA, mAb-
193 recognized only PY-ERK-BSA and ¢nally, the GPY anti-
body recognized both PY-ERK-BSA and DP-ERK-BSA.
Thus, this set of ¢ve antibodies (TY, 155, 115, 193 and
KGPY) appears to be capable of distinguishing between all
the possible phosphorylation states of the TEY peptides.
The antibodies were further characterized by examining the
ability of various peptides to compete with the antibodies for
binding to BSA-conjugated peptides in a competitive ELISA
(Fig. 2). As previously reported, the binding of mAb-TY to
the DP-TEY-BSA was abolished only by the DP-TEY peptide
[18]. mAb-155 was not as speci¢c, and in competitive inhibi-
tion assays of its binding to PT-TEY-BSA, the IC50 of PT-
TEY was about 0.5 Wg/ml whereas the IC50 of NP-TEY was
6 Wg/ml, indicating that mAb-155 appears to recognize PT-
TEY best, but may interact also with NP-ERK. Another anti-
body that demonstrated speci¢city for PT-TEY was mAb-115,
which di¡ers from the mAb-155 in that both PT-TEY and
DP-TEY inhibited its binding to PT-ERK-BSA with almost
the same IC50 (V5 Wg/ml). Therefore, mAb-115 appears to
recognize phosphorylated Thr in TEY peptides independent
of whether the adjacent Tyr residue is phosphorylated. In
addition to the two anti-PT-ERK antibodies, we examined
mAb-193 and found that its binding to PY-TEY-BSA was
speci¢cally displaced only by PY-TEY (IC50 of 3 Wg/ml),
which indicated its speci¢city for the mono-phosphorylated
PY-TEY. The unique speci¢city of the antibodies (Table 1),
which can distinguish between the di¡erent phosphorylation
states of ERK, should make them a useful tool in the study of
ERK regulation upon extracellular stimulation.
3.2. Changes in ERK phosphorylation upon mitogenic
stimulation of CHO.E cells
The anti-phospho-ERK antibodies were used to monitor
the phosphorylation states of ERK upon mitogenic stimula-
tion in CHO cells stably transfected with EGF receptor
(CHO.E). Thus, serum-starved CHO.E cells were stimulated
with EGF for various periods, and the cell lysates were sub-
jected to SDS^PAGE followed by Western blot analysis with
the various antibodies (Fig. 3). The results obtained with the
anti-general ERK, pAb 7884 con¢rmed that essentially equiv-
alent amounts (6 10% di¡erences) of ERKs were loaded in
each lane, allowing to interpret variations in staining inten-
sities by the various antibodies as changes in the amount of
incorporated phosphates to the appropriate Tyr and Thr res-
idues. Up to four bands can be detected with the various
antibodies, these are ERK1, shifted (phosphorylated) ERK1,
ERK2 and shifted (phosphorylated) ERK2. Although only
the results obtained with ERK2 will be described, similar
results were obtained for ERK1.
When the cell lysates were subjected to Western blot anal-
ysis with mAb-TY, the dually phosphorylated ERK2 ap-
peared within 2 min of EGF stimulation, peaked within
6 min and declined after an additional 9 min (Fig. 3). We
then examined the pattern of phosphorylation with mAb-
155, which recognizes both Thr-phosphorylated and non-
phosphorylated TEY peptide. Since only the minority of
ERK2 became phosphorylated, as can be judged from the
small amount of shifted ERK2 (Fig. 3, 7884), it can be con-
cluded that the upshifted band was detected by mAb-155 in a
more e⁄cient manner than the non-phosphorylated ERK2
(lower band). The accumulation of PT-ERK was therefore
detected from the intensity of the shifted band. Thus, the
PT-ERK2 was detected already 2 min after activation, peaked
at 8 min after stimulation and decreased, in similar (or some-
times slightly slower) kinetics, to that obtained with the DP-
ERK antibodies. As would be expected from this similarity,
when the state of ERK phosphorylation was examined using
the mAb-115, which recognizes DP-TEY and PT-TEY, the
Fig. 2. Speci¢city of the anti-phospho-ERK antibodies using com-
petitive ELISA. 96 Well plates were coated with the appropriate
BSA-conjugated peptides (PT-TEY for 155 and 115, PY-TEY for
193 and DP-TEY for TY; 1 Wg/ml each). The various antibodies
were added (50 ng/ml) together with the indicated amount of the
PT- b, PY- a, DP- F or NP- E TEY peptides and with DP pep-
tides derived from the activation loops of p38 MAPK X and of
JNK R (N: no peptide). The binding was detected with peroxidase-
conjugated goat anti-mouse. The results here are from a representa-
tive experiment that was reproduced ¢ve times.
Table 1
Speci¢city of the anti-phospho-ERK antibodies
NP-ERK PT-ERK PY-ERK DP-ERK
mAb-TY 3 3 3 +++
mAb-155 + +++ 3 3
mAb-115 3 +++ 3 ++
mAb-193 3 3 +++ 3
KGPY þ þ ++ ++
This table summarizes the speci¢cities of the various antibodies to
the di¡erent phosphorylation states of ERK according to the di¡er-
ent parameters used (direct ELISA, competitive ELISA, recognition
of ERK mutants and gel-shift as shown in Figs. 1^3). +++ High
speci¢city, ++, medium speci¢city, + low speci¢city, 3 no recogni-
tion.
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results obtained were also similar to those obtained with
mAb-TY and with mAb-155 (Fig. 3, 115).
In contrast to the similar time course observed with mAb-
TY, mAb-155 and mAb-115, the kinetics of phosphorylation
observed with the antibodies which recognize PY-ERK (mAb-
193 and KGPY) were signi¢cantly di¡erent from the kinetics
of the DP-ERK2 appearance. Thus, the accumulation of PY-
ERK2 upon EGF stimulation, which was detected with mAb-
193, was transient, peaked at 6 min after stimulation and
sharply declined to basal levels. Then, the accumulation of
phosphorylated Tyr-183 in ERK2, either in the presence or
the absence of phosphate on Thr-185, was detected by the
general anti-phosphotyrosine antibody pAb KGPY. The ki-
netics of this phosphorylation appeared similar to that de-
tected by mAb-193 and not to that detected by mAb-TY.
This similarity between the pro¢les detected by mAb-193
and of GPY indicates that the amount of mono-phosphory-
lated PY-ERK produced after activation is larger than that of
the dually phosphorylated ERK, and therefore PY-ERK is
the main contributor to the pro¢le obtained with the pAb
KGPY.
Mono-phosphorylated PY-ERKs can be formed by two
distinct mechanisms including phosphorylation by MEK,
which phosphorylates Tyr-183 before it can phosphorylate
Thr-185 [25], or by pSer/Thr phosphatases which dephosphor-
ylate the phosphothreonyl residue of DP-ERK. In addition,
the level of PY-ERK can be regulated by the removal of the
phosphate from Tyr-183 or by phosphorylation on the adja-
cent Thr-185 to form a DP-ERK which is not recognized by
the mAb-193. Our results show that MEK activation, under
the condition used, peaks 4 min after activation, and reduces
back to basal levels within 12 min (data not shown). However,
since the phosphorylation of the two regulatory residues of
ERK after EGF stimulation occurs almost simultaneously ([8]
and data not shown), selective phosphorylation by MEK on
Tyr-183 alone probably cannot account for the production of
the large amount of PY-ERK described above. On the other
hand, it is likely that the accumulation of PY-ERK is carried
out and regulated by various phosphatases. Thus, the increase
in the amount of mono-phosphorylated PY-ERK probably
occurs due to removal of the phosphate from the Thr residue
of the DP-ERK. The decrease in the amount of PY-ERK is
most probably due to the removal of the phosphate from the
Tyr-183 of ERK2 and not due to rephosphorylation by the
residual activity of MEK. Therefore, the high amount of PY-
ERK formed in the CHO.E cells after EGF stimulation (Fig.
3, 193) is likely to occur by constitutively active protein Ser/
Thr phosphatases, which can remove the phosphate from the
Thr but not the Tyr residues of ERKs, and which have been
reported to play a role in the inactivation process of ERK
[15]. In addition, the existence of a signi¢cant amount of
mono-phosphorylated PT-ERK described above and the
sharp decline in the amount of PY-ERK in the absence of
signi¢cant MEK activity indicate that as suggested [26], PTP
is also involved in the mechanism of ERK dephosphorylation.
The accumulation of PY-ERK2 6 min after stimulation, and
the slower time course of appearance of mono-phosphorylated
PT, would predict that the cellular activity of this putative
PTP is lower than that of the protein Ser/Thr phosphatase.
However, the sharp reduction in amounts of PY-ERK2 at
8 min after stimulation suggests that an additional PTP with
di¡erent mode of regulation may be involved in the later
stages of ERK’s dephosphorylation as will be discussed be-
low.
Another conclusion that can be drawn from our results is
that the slow migrating (shifted) band of ERKs contains not
only the active, dually phosphorylated form, but also the
mono-phosphorylated forms of ERK2. Thus the slower mi-
gration of ERK on SDS^PAGE does not always correlate
with the actual ERK activity, especially during inactivation
processes as observed here (Fig. 3). Therefore, the use of the
‘upshift assay’ to study ERK activation may not always be
accurate.
3.3. Intracellular distribution of phosphorylated ERKs
In order to study the subcellular distribution of the various
phosphorylated forms of ERKs, we have used the di¡erent
anti-phospho-ERK antibodies in immunohistochemical stud-
ies. The appearance of mono-phosphorylated and dually
phosphorylated ERKs (Fig. 4) showed similar kinetics to
that observed by the immunoblotting studies (Fig. 3), they
peaked at about 5 min after stimulation and returned to the
basal states within 15 min. In resting CHO.E cells, ERKs were
localized in the cytoplasm, as revealed by pAb 7884 (Fig. 4).
Nuclear translocation of ERK was observed 5 min after EGF
stimulation and this nuclear localization was diminished
15 min after stimulation. When mAb-TY was used for immu-
Fig. 3. Time courses of EGF-induced ERK phosphorylation in
CHO.E cells. A: Serum-starved CHO.E cells were stimulated with
EGF (50 ng/ml) for the indicated times. Cell lysates were then sub-
ject to Western blot analysis with the various mAbs, anti-general
phosphotyrosine antibody (KGPY) or anti-general ERK antibody
(pAb 7884). The places of ERK2 and its ‘shifted’ form (ERK2*)
and that of ERK1 and its ‘shifted’ form (ERK1*) are indicated. B:
The intensity of staining of the upper band of ERK2 by mAbs-TY,
155 and 115 (left panel) and TY, 193 and pAb KGPY (right panel)
were determined as percentage of maximal intensity of each anti-
body. The results are from a representative experiment that was re-
produced three times.
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no£uorescent staining in resting CHO.E cells, a faint staining
was detected mainly in the cytoplasm. Stimulation with EGF
(5 min) caused an increased staining with mAb-TY, in the
cytoplasm and in the nucleus, whereas 15 min after stimula-
tion, the staining intensity reduced again and was localized
mainly to the cytoplasm. Detection of the distribution of
PT-ERK with mAb-155 revealed that in resting CHO.E cells,
a small amount of PT-ERK was detected, mainly in the cy-
tosol. Upon EGF stimulation (5 min), the intensity of staining
with mAb-155 increased, accumulating mainly in the cytosol
and perinuclear regions, and the pattern of staining returned
to that of resting cells 15 min after stimulation. The distribu-
tion of PY-ERK detected with mAb-193 was quite di¡erent
from that of PT-ERK. It was very faint and uniformly dis-
tributed in resting cells, increased mainly in the nucleus (5 min
after stimulation) and the staining returned to near-basal state
10 min later.
The di¡erent distribution of various phosphorylated ERKs
suggests a di¡erent localization of various PPs that di¡eren-
tially regulate ERK dephosphorylation. Since PT-ERK was
detected mainly in the cytoplasm, the involved PTP should
also be localized in this region. This conclusion is in agree-
ment with the recent reports that PTP-SL, STEP [26] and
PTP-ER [27] are localized in cytoplasm. Similarly, the exis-
tence of PY-ERKs in the nucleus indicates that the involved
protein Ser/Thr phosphatases should be localized, at least in
part, in the nucleus. An interesting possibility for the protein
Ser/Thr phosphatase responsible for the accumulation of PY-
ERK in the nucleus is the well characterized PP2A, which was
previously shown to be localized both in the cytoplasm and in
the nucleus [28]. However, it should be noted that additional
phosphatases are required in each of the subcellular compart-
ments in order to bring ERK phosphorylation back to basal
levels. Therefore, after the initial dephosphorylation by pro-
tein Ser/Thr phosphatase in the nucleus, a complementary
PTP is required to remove the phosphate from Tyr-185, and
similarly, an additional protein Ser/Thr phosphatase is re-
quired in the cytoplasm. Thus, the temporal and spatial reg-
ulation of ERK is dependent on various phosphatases that
cooperate to secure the proper length and strength of ERK
activity, which eventually determine the physiological out-
come of variou extracellular signalings [29].
In summary, we describe here a set of antibodies, which are
shown to recognize speci¢cally all phosphorylation states of
ERK (Table 1). These antibodies can serve as a useful tool to
investigate mechanisms of ERK activation and downregula-
tion. We found that in CHO.E cells, the early phase of ERK
dephosphorylation is carried out by distinct, constitutively
active protein Ser/Thr and protein Tyr phosphatases. These
processes are undertaken in a spatially characteristic pattern.
Dephosphorylation of the phosphotyrosyl residue of the du-
ally phosphorylated ERK is the ¢rst dephosphorylation pro-
cess in the cytoplasm, whereas dephosphorylation of the phos-
phothreonyl residue is the initial one in the nucleus. These
processes are later complemented by distinct phosphatases
to secure a complete removal of phosphates from ERK, bring-
ing it back to the basal, non-phosphorylated stage. Using the
various anti-phospho-ERK antibodies, we also concluded that
the slow migrating band of ERKs on SDS^PAGE gel con-
tains not only the active, dually phosphorylated form, but
also the mono-phosphorylated forms of ERK2. Thus the
use of ‘upshift’ assay to study ERK activation may not always
be accurate.
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Fig. 4. Immuno£uorescent staining of EGF-induced CHO.E cells with the anti-phospho-antibodies. CHO.E cells were grown on microslides for
8 h, serum-starved for 40 h and stimulated with EGF (50 ng/ml). The cells were ¢xed, permeabilized and stained with the various antibodies
(pAb 7884 and mAbs-TY, 155 and 193; 100 Wg/ml each) and Cy3-conjugated second antibodies as above. The results were reproduced twice.
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